Longwood Fund

Longwood Fund is a Boston-based venture firm focused exclusively on early-stage life sciences company creation and investment, with a focus on biotech and pharma and therapeutics. The firm participates actively in forming new companies around promising scientific platforms and supports founders and management teams as they translate biology into clinical programs. Its Boston location places it at the heart of one of the world’s most active biotech ecosystems, with proximity to leading academic medical centers, research institutions, and specialist life sciences investors and operators. Specific portfolio companies and named partners are not provided in the input, so this profile emphasizes the firm’s stated focus and structural posture.

Longwood writes checks of $5M to $25M and invests at Pre-Seed, Seed, and Series A stages. Headquartered in the United States, the firm engages early in a company’s life, often during formation or first institutional rounds, and supports the team through initial scientific validation and the move toward clinical development. The early-stage focus places the firm close to the most formative decisions about science, IP, and team.

For founders and scientific founders, Longwood is most relevant when a program is built around a strong biological hypothesis and would benefit from a partner experienced with company creation, founding-team assembly, and the early steps of life sciences company building. The firm prefers rigorous engagement on science, IP, and clinical strategy. Founders should expect a partner that brings deep biotech network depth, hands-on involvement in early company building, and patience with the long arcs typical of drug development.